Xiaoyang Ma

Xiaoyang Ma is a Managing Partner at Amphora Capital, a Chinese private equity and venture capital firm founded in 2006 as the private-investment arm of the Amphora group. The firm is headquartered in Beijing (with roots and offices in Shandong Province, including Jinan and Qingdao) and manages a fund scale reported at roughly RMB 10–20 billion, having backed more than 300 enterprises over 15+ years, dozens of which have gone public.

Within the partnership, Ma's mandate is centered on the firm's human-resources and administrative organization rather than deal origination. According to Amphora's own team page, he holds a bachelor's degree in Law with a specialization in Economic Law from Southwestern University of Finance and Economics, and brings more than eight years of experience in human resources and administration at high-tech listed group companies. He is credited as a "national first-level (senior) enterprise human resource manager" and is described as skilled in the formation, management, and operation of HR and administrative teams.

He sits among Amphora's core leadership alongside Founder/Chairman Julia Zhou, founding partners Sindi Wu and Li Qinlian, and partner Yi Zou, in a team of roughly two dozen professionals spanning fund management, investment, risk control, and post-investment functions. Note that public investor databases (e.g., EasyVC) surface his contact as that of an "Angel Investor / Seed" contact at the firm; in practice Amphora is a multi-stage VC/PE house, and Ma's role is an operational/managing-partner one rather than that of a lead deal partner.

• Firm strategy targets startup and growth-stage companies in "high-precision technology" fields: healthcare/biopharma, commercial aerospace, industrial Internet, and high-end equipment manufacturing (plus new materials and intelligent manufacturing).
• Stated firm philosophy emphasizes "trend analysis, value investment, win-win cooperation," with core values of honesty toward investors, portfolio companies, and society.
• Biopharma is a notable theme: the firm has backed new-drug companies including Anke Biotechnology and TCR/other biologics projects, plus medical-informatization and medical-device deals.
• Track record leans toward companies that can reach public markets in China (ChiNext/A-share) and abroad — the firm highlights multiple IPO exits as evidence of its growth-stage focus.
• Ma personally adds value on the organizational/operational side (HR, administration, team-building) rather than as a thesis-driven sector investor.